STAT+

Health tech Brittany Trang

STAT Plus: Bipartisan task force sets health AI oversight priorities for the next Congress

Health Lizzy Lawrence

STAT Plus: FDA deputy commissioner Namandjé Bumpus to leave agency

D.C. Diagnosis Sarah Owermohle

STAT Plus: PBMs face scrutiny from all sides, and analyzing Marty Makary’s road to the FDA

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Congress reining in PBMs, Sanofi suing HHS, and more

Pharmalot Ed Silverman

STAT Plus: Sanofi is the latest drug company to sue HHS over payment terms for 340B hospitals

Pharma Matthew Herper

STAT Plus: Pfizer’s 2025 forecast meets expectations and leaves room for debate

First Opinion David Balto

STAT Plus: Pharmacy benefits managers should be worried

Politics Lizzy Lawrence

STAT Plus: Truth-teller or reflexive contrarian: Which Marty Makary would run the FDA?

Adam's Take Adam Feuerstein

STAT Plus: Who stood out as Best Biopharma CEO of 2024? 

Politics Rachel Cohrs Zhang

STAT Plus: Congress strikes deal to rein in PBMs after years of debate

Health Care Inc. Newsletter Bob Herman

STAT Plus: The AI denial fighters and health care’s rising profitability

Health tech Katie Palmer

STAT Plus: FDA authorizes many AI devices for use in kids. Are they validated in a pediatric population?

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Novo Holdings proceeding with Catalent deal, Sanofi threatened with sanctions, and more

First Opinion Sadiq Y. Patel

STAT Plus: How AI can help bring better care to Medicaid patients

Politics John Wilkerson

STAT Plus: Three major health care policy issues to watch in 2025

Business Chris Serres, Liz Kowalczyk, Elizabeth Koh, and Brendan McCarthy — Boston Globe

STAT Plus: Broken promises, lax scrutiny: Inside Massachusetts’s failure to regulate Steward Health

Pharmalot Ed Silverman

STAT Plus: Novo Holdings is set to close its $16.5 billion acquisition of Catalent after FTC declines to challenge the deal

Pharmalot Ed Silverman

STAT Plus: Feds threaten Sanofi with sanctions over plan to change payment terms for a federal drug discount program

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Editas layoffs, House Republicans probing CVS, and more

Biotech Jonathan Wosen and Matthew Herper

STAT Plus: Ionis blazed trails in genetic medicine. On the cusp of a major approval, can it also be a commercial success?

Pharma Angus Chen

STAT Plus: For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission

Pharmalot Ed Silverman

STAT Plus: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players, report finds

Biotech Jason Mast

STAT Plus: Editas Medicine lays off 65% of staff and shelves lead gene-editing program

Insurance Bob Herman

STAT Plus: Centene warns Republicans against cutting Medicaid or letting ACA subsidies expire

Biotech Adam Feuerstein

STAT Plus: Investors in Padlock Therapeutics sue Bristol Myers Squibb over ‘milestone’ payments

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more

Pharma Matthew Herper

STAT Plus: Pfizer’s blockbuster Ibrance slows tumor progression in another type of breast cancer

Pharmalot Ed Silverman

STAT Plus: Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds